Oncopeptides to highlight clinical progress and present new data at the IMS Annual Meeting

As the defining annual gathering in the myeloma field, the IMS congress provides an important platform for Oncopeptides to showcase significant corporate and clinical momentum achieved over the past year. Since the society's meeting last year, Oncopeptides has advanced across multiple fronts—accelerating commercial execution in Europe, expanding regional distribution through strategic partnerships, strengthening clinical evidence for Pepaxti (melflufen), and broadened the scope of its proprietary Peptide-Drug Conjugate (PDC) platform into new therapeutic indications such as glioblastoma.

For the congress, a poster evaluation titled: "Impact of prior Daratumumab or Isatuximab: an analysis of relapsed and refractory multiple myeloma (RRMM) patients treated with melflufen plus dexamethasone in the OP-106 HORIZON study" has been accepted. Led by prominent international investigators, the analysis explores clinical outcomes among heavily pretreated patients stratified by prior anti-CD38 monoclonal antibody exposure, offering further hypothesis-generating insights into treatment sequencing in modern clinical practice.

"As we return for the annual IMS congress, our real-world evidence programs are maturing, and our scientific understanding of PDCs continues to deepen," says Stefan Norin, Chief Medical Officer at Oncopeptides. " Our presence in Glasgow allows us to engage directly with the global myeloma community and share how Pepaxti continues to offer a vital, differentiated treatment option for patients with high unmet medical needs who have exhausted other alternatives."

Please visit the IMS website to view the poster. For more information on Oncopeptides' ongoing clinical programs, please visit www.oncopeptides.com.